CRISPR Therapeutics registers Phase 1/2 trial of CTX340 for treatment-resistant hypertension
CTX340, a CRISPR-Cas9 gene editing therapy targeting the AGT gene, is listed as recruiting for participants with uncontrolled, treatment-resistant hypertension.
CRISPR Therapeutics AG has one hypertension program listed in the registry this week.
- CTX340 is an in vivo gene editing therapy designed to utilize CRISPR-Cas9 to target and disrupt the human angiotensinogen (AGT) gene in the liver1, and the study is currently listed as recruiting, with an estimated start date of 2026-08-08. The trial is a Phase 1/2 multicenter, first-in-human, ascending dose trial1 that will enroll 69 participants (estimated)1. Eligible participants must have a 24-hour mean ambulatory blood pressure monitoring systolic blood pressure of 130 to 160 mm Hg despite being on at least 4 antihypertensive therapies, including at least one diuretic1. The Phase 2 portion's primary outcome is the percentage change in circulating angiotensinogen (AGT) concentration from baseline through 6 months of follow-up1.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.